<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00158678</url>
  </required_header>
  <id_info>
    <org_study_id>GORTEC 2004-01</org_study_id>
    <nct_id>NCT00158678</nct_id>
  </id_info>
  <brief_title>IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC</brief_title>
  <official_title>Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Oncologie Radiotherapie Tete et Cou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Oncologie Radiotherapie Tete et Cou</source>
  <brief_summary>
    <textblock>
      This is a multicentric randomized phase III trial comparing intensity-modulated radiotherapy
      (75 Gy) plus cisplatin versus conventional radiotherapy (70 Gy) plus cisplatin in patients
      with stage III-IV squamous cell carcinoma of oral cavity, oropharynx or hypopharynx. The main
      end points are the rate of locoregional control and the rate of xerostomia at 2 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentric randomized phase III trial comparing intensity-modulated radiotherapy
      plus concomitant cisplatin versus conventional radiotherapy plus concomitant cisplatin in
      patients with stage III-IV squamous cell carcinoma of oral cavity, oropharynx or hypopharynx.
      The main end points are the rate of locoregional control and the rate of xerostomia at 2
      years.

      The IMRT total dose is 75 Gy (50 Gy to PTV1 and T0 + 25 Gy (10 fractions) to PTV2). The
      conventional radiotherapy total dose is 70 Gy (50 Gy to PTV1 + 20 Gy (10 fractions) to PTV2).
      In both arms, the cervical nodes will receive 50 Gy (65 Gy in case of Np) by conventional
      radiotherapy (IMRT is allowed in the IRMT arm). In the two arms, patients will receive
      concomitant cisplatin (100 mg/mÂ² D1, D21, D42).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Loco regional control</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Xerostomia at 2 years (evaluated by parotid gland scintigraphy)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (EORTC-QLQ-H&amp;N35)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Oral Cancer</condition>
  <condition>Oropharynx Cancer</condition>
  <condition>Hypopharynx Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional RT 70Gy + concomitant cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMRT 75Gy + concomitant cisplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IMRT 75 Gy</intervention_name>
    <description>50 Gy in PTV1 and 25 Gy in 10 fractions in PTV2</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional radiotherapy 70 Gy</intervention_name>
    <description>50 Gy in PTV1 and 20 Gy in PTV2</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>concomitant cisplatin</intervention_name>
    <description>100 mg/m2 D1, D22, D43</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  squamous cell carcinoma of oral cavity, oropharynx or hypopharynx

          -  Stage III - IV (T1-T4, N0-N2)(UICC 2002)

          -  Not resected

          -  Indication of radiotherapy to bilateral cervical nodes at dose&gt;= 50 Gy

          -  Delineation of target volumes done before randomization

          -  Scintigraphy of parotid gland done before radiotherapy start

          -  Quality of life questionnaires (EORTC-C30 and EORTC-H&amp;N35) filled in by the patient

          -  Informed consent signed

        Exclusion Criteria:

          -  N3 (UICC 2002)

          -  Distant metastasis

          -  Contra-indication to concomitant cisplatin

          -  History of cancer within the last 5 years

          -  History of head and neck radiotherapy

          -  Administration of drugs for treatment or prophylaxis of xerostomia (pilocarpine,
             ethyol)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Bourhis, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel Lapeyre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Alexis Vautrin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.gortec.org</url>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oral cancer</keyword>
  <keyword>oropharynx cancer</keyword>
  <keyword>hypopharynx cancer</keyword>
  <keyword>IMRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mouth Neoplasms</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Hypopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

